These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 1497575

  • 1. Dysfunction of the ADP/ATP carrier as a causative factor for the disturbance of the myocardial energy metabolism in dilated cardiomyopathy.
    Schultheiss HP.
    Basic Res Cardiol; 1992; 87 Suppl 1():311-20. PubMed ID: 1497575
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ventricular adenine nucleotide translocator mRNA is upregulated in dilated cardiomyopathy.
    Sylvén C, Lin L, Jansson E, Sotonyi P, Fu LX, Waagstein F, Hjalmarsson A, Marcus C, Brönnegård M.
    Cardiovasc Res; 1993 Jul; 27(7):1295-9. PubMed ID: 8252591
    [Abstract] [Full Text] [Related]

  • 6. Disturbance of the myocardial energy metabolism in dilated cardiomyopathy due to autoimmunological mechanisms.
    Schultheiss HP.
    Circulation; 1993 May; 87(5 Suppl):IV43-8. PubMed ID: 8485833
    [Abstract] [Full Text] [Related]

  • 7. Effect on the myocardial energy metabolism of angiotensin-converting enzyme inhibition in chronic heart failure.
    Schultheiss HP.
    Am J Cardiol; 1990 Apr 03; 65(14):74G-81G. PubMed ID: 2321555
    [Abstract] [Full Text] [Related]

  • 8. The myocardial expression of the adenine nucleotide translocator isoforms is specifically altered in dilated cardiomyopathy.
    Dörner A, Schultheiss HP.
    Herz; 2000 May 03; 25(3):176-80. PubMed ID: 10904836
    [Abstract] [Full Text] [Related]

  • 9. Myocardial adenine nucleotide concentrations and myocardial norepinephrine content in patients with heart failure secondary to idiopathic dilated or ischemic cardiomyopathy.
    Regitz V, Fleck E.
    Am J Cardiol; 1992 Jun 15; 69(19):1574-80. PubMed ID: 1598872
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Functional analysis of autoantibodies against ADP/ATP carrier from dilated cardiomyopathy.
    Liao YH.
    Int J Cardiol; 1996 May 15; 54(2):165-9. PubMed ID: 8803681
    [Abstract] [Full Text] [Related]

  • 14. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts.
    Schwinger RH, Böhm M, Schmidt U, Karczewski P, Bavendiek U, Flesch M, Krause EG, Erdmann E.
    Circulation; 1995 Dec 01; 92(11):3220-8. PubMed ID: 7586307
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of the ADP/ATP carrier in the pathogenesis of viral heart disease.
    Schulze K, Schultheiss HP.
    Eur Heart J; 1995 Dec 01; 16 Suppl O():64-7. PubMed ID: 8682105
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of ATP precursors on ATP and free ADP content and functional recovery of postischemic hearts.
    Ambrosio G, Jacobus WE, Mitchell MC, Litt MR, Becker LC.
    Am J Physiol; 1989 Feb 01; 256(2 Pt 2):H560-6. PubMed ID: 2916688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.